



GREECE

Dr GEORGINA TZANAKAKI

HEAD, NATIONAL MENINGITIS REFERENCE LABORATORY

NATIONAL SCHOOL OF PUBLIC HEALTH

General information



| | | |
|--|--|---|
| Population size | Category | 11 103 929 |
| Structure of surveillance of meningococcal disease | Statutory notification of disease | Yes |
| | Enhanced surveillance | No |
| NRL: repertoire of typing targets | Centralized Laboratory Surveillance | Yes |
| | Serogroup | Yes |
| | PorA antigen sequence typing | Yes |
| | FetA antigen sequence typing | Yes |
| | Vaccine Antigen sequence typing (e.g. fhbp) | Yes (since 2015) |
| | Antibiotic resistance gene typing | No |
| Meningococcal vaccine recommendation | MLST (7 loci) | Yes |
| | Genome sequencing | Yes (since 2015) |
| | Polysaccharide vaccines (not conjugated) | No |
| | MenC conjugate | YES (since 2005) |
| | MenACWY conjugate | YES (since 2010) |
| | Protein vaccines targeting MenB | No (officially although in private market) |
| Uptake of MenWY vaccines | estimated % per target group size | 60-70% in adolescents |

Basic numbers for 2015




| | |
|--|---|
| <p>No of reported cases of invasive meningococcal disease * (incidence rate)</p> | <p>N=57 cases (0,52 /100,000)</p> |
| <p>Proportion of reported cases of invasive meningococcal disease, whose strains or samples were processed at NRL (=laboratory surveillance coverage of reported cases)</p> | <p>90%</p> |
| <p>MenW</p> <ul style="list-style-type: none"> • no of cases, • incidence rate, • % of all cases | <p>N=0</p> |
| <p>MenY</p> <ul style="list-style-type: none"> • no of cases, • incidence rate, • % of all cases | <p>N=4 0,04/100,000 7,1%</p> |


* [ECDC case definition](#)

Nov. 1st, 2016


Incidence rates for serogroups B, C, W, Y [2006-2016 (Oct)]



Age specific incidence rates 2015 /2016 (Oct) for serogroups W and Y in Greece




Case fatality rates 2015 for serogroups B, C, W, Y



Sequence typing of **MenW** in 2015



| Year | 2015 |
|------------------------------------|--|
| porA |  NO CASES |
| MLST (of all MenW cases) | |
| cc11 in of all serogroup W* cases | |

Sequence typing of **MenY*** in 2015



| Year | 2015 |
|--|---|
| porA | 5-1, 10-1 (VR-1 & VR-2 respectively) |
| MLST (of all MenY* cases) | 23 cc 100 % (4/4) |
| cc11 in of all serogroup W* cases | NONE |

Outbreaks caused by serogroups W and Y 2012 - 2016

